Bioarctic BIOA B
This picture changes. Follow Bioarctic free — email when the signal or risk changes + a Sunday weekly brief.
Follow Bioarctic freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 13 Jul 2026
General analysis — not personal advice.
BUY
8/10
Confidence
Consider scaling in (e.g., 5–15%) rather than adding all at once: partly ahead of AAIC (July 12–15) and the remainder into the Q2 report on Aug 26, as newsflow may increase volatility.
ADD remains: the Lilly agreement is strong third-party validation of BrainTransporter and adds a new potential value driver beyond Leqembi royalties. However, partner dependence and clinical risk remain, and near-term valuation may be more stretched after the deal-driven move.
Market sentiment
7/10
↑
Trend: Improving
Sentiment has modestly improved after the Lilly deal (platform validation and meaningful upside optionality), but is tempered by concerns that the stock may already price in optimism and by ongoing uncertainty around Alzheimer commercialization/reimbursement execution.
Risk assessment
6/10
Dilution:
Low
Strong cash position and recurring royalty income; the EUR 20m milestone further strengthens liquidity and reduces the need for external financing.
Jurisdiction:
Low
Sweden and Western regulatory markets
Execution:
Medium
Partner dependence and pipeline clinical risk
Cash flow:
36 mo
Recent changes
- ▲ Sentiment improved (6→7) after the Lilly deal, which validates BrainTransporter and adds a new value driver beyond Leqembi royalties.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
BioArctic is a Swedish biotech company developing disease-modifying therapies for neurodegenerative diseases. The company has rapidly growing income from royalties and licenses, primarily tied to the Alzheimer’s drug Leqembi (lecanemab) through partner Eisai. Beyond Leqembi, BioArctic is advancing a Parkinson/ALS pipeline and the BrainTransporter™ platform for drug delivery across the blood-brain barrier.
Sector:
Biotechnology and pharmaceuticals (neurodegenerative diseases)
Type:
Biotech
Next report
26 Aug 2026
Q2
Catalysts
24 Aug 2026
FDA PDUFA: Leqembi Iqlik (SC starting dose)
High
26 Aug 2026
Q2 / Half-year report 2026
Medium
Q3 2026
Exidavnemab Phase 2a: approaching readout
Medium
Horizon:
Bull case
The Q1 report may confirm continued acceleration in Leqembi royalties.
- Positive flow around subcutaneous Leqembi regulatory progress.
- Ongoing momentum after strong FY/Q4 results and profitability.
Bear case
High expectations could trigger a pullback on any sales miss.
- Regulatory delays/setbacks for the subcutaneous formulation.
- FX and broader market volatility may pressure the share short term.
Signal rationale (informational)
ADD remains: the Lilly agreement is strong third-party validation of BrainTransporter and adds a new potential value driver beyond Leqembi royalties. However, partner dependence and clinical risk remain, and near-term valuation may be more stretched after the deal-driven move.
Recent news
- No new company-specific press releases or major news have been identified after 2026-07-02. Focus remains on (1) BioArctic’s research and collaboration agreement with Eli Lilly (announced 22 June 2026; $30m upfront, up to $770m milestones plus royalties; Lilly leads further development/commercialization) and (2) upcoming lecanemab/Leqembi data presentations at AAIC July 12–15 (incl. subcutaneous formulation, long-term/RWE data, maintenance dosing and at-home treatment) via partner Eisai.
Price & valuation
Last close
SEK 319
1 week
+2.8 %
3 months
-1.3 %
12 months
+45.0 %
From 52w high
-12.5 %
From 52w low
+47.7 %
Exchange
Stockholm
Type
Biotech
Sector
Biotechnology and pharmaceuticals (neurodegenerative diseases)
This picture changes. Follow Bioarctic free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.